164
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients

, , &
Pages 142-146 | Received 30 Dec 2016, Accepted 02 May 2017, Published online: 06 Jun 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Luo Qiong & Jun Yin. (2022) Characterization of alpha-1-acid glycoprotein as a potential biomarker for breast cancer. Bioengineered 13:3, pages 5818-5826.
Read now
Marit Vermunt, Serena Marchetti & Jos Beijnen. (2021) Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials. Clinical Pharmacology: Advances and Applications 13, pages 21-32.
Read now

Articles from other publishers (2)

Stanislav Naryzhny, Natalia Ronzhina, Elena Zorina, Fedor Kabachenko, Nikolay Klopov & Victor Zgoda. (2022) Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers. International Journal of Molecular Sciences 23:19, pages 11113.
Crossref
Yu-Fen Xu, Yao Xu, Xia Li & Xin-Mei Yang. (2019) Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma. Combinatorial Chemistry & High Throughput Screening 21:10, pages 755-759.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.